This 4+ Year Old Website Has 1,000+ High Quality Articles
Written By Qualified Experts After Thorough Research.
As An Authority INFORMATIONAL Website, It Is Updated DAILY.
You Should Always Revisit For Latest On Prostate Cancer!

ConfirmMDx(TM) Helps to Avoid Repeat Biopsies On Prostate Cancer

An epigenetic test for prostate cancer known as ConfirmMDX(TM) can now be used by Urologists to detect or screen early prostate cancer.

Data from the makers MDxHealth SA confirms that Urologists can use it to different patients who might be having real prostate cancer and those who are not.

The unpleasant and sometimes unnecessary repeat of tissues biopsies to stage prostate cancer would be avoided.

A study was made to arrive at the findings made by the company. Details of the study and further informaton about this epigenetic test for prostate cancer are provided below:

MDxHealth SA (nyse euronext:MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced it has presented data demonstrating that its epigenetic ConfirmMDx(TM) for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy.

In men suspected to have prostate cancer, the potential for false-negative biopsy results is well documented in the literature. Approximately twenty-five percent of men receiving a negative histopathology result, the gold standard for diagnosis, could be harboring occult cancer. Fear over this issue leads to additional physician visits, screening, and repeat biopsies, often on prostate-cancer-free men. MDxHealth’s ConfirmMDx test assesses the DNA methylation status of genes associated with prostate cancer. The test will help urologists differentiate patients with a true-negative biopsy from those who may have cancer undetected by prostate biopsy and histopathological review.

The data from the MATLOC (Methylation Analysis To Locate Occult Cancer) study presented during the Late Breaking Science Forum yesterday at the American Urology Association (AUA) Annual meeting in Atlanta, USA, revealed that the ConfirmMDx for Prostate Cancer test is a powerful tool to aid urologists in addressing false-negative biopsy concerns.

“With a high negative predictive value, exceeding that of standard microscopic histopathology review, the MATLOC study results demonstrate that the ConfirmMDx for Prostate Cancer test can help urologists confirm true-negative biopsy results, providing peace-of-mind and reducing unnecessary repeat biopsies,” explained principle investigator Dr. Grant Stewart from the Edinburgh Urological Cancer Group at the University of Edinburgh, who presented the data. “The test will also help urologists identify high-risk men who may have occult cancer, enabling more effective triage of these patients with a repeat biopsy and treatment as required.”

“These data confirm the high negative predictive value (NPV) and clinical utility of the ConfirmMDx for Prostate Cancer genes and DNA methylation technology previously reported in published studies. We believe the test fulfills an unmet medical need, complementing the current standard of care, and holds the potential to reduce unnecessary invasive procedures and the associated healthcare expenditures. Prostate biopsies pose significant risk of trauma and infection, at times requiring hospitalization. As a consequence, approximately one-third of men refuse to endure a repeat biopsy despite fear of a false-negative result, leaving these men at risk for disease progression. ConfirmMDx, a non-invasive assay performed on the residual prostate tissues from the previous negative biopsy, provides critical insights beyond histopathology to enable more informed patient management decisions,” said Dr. Jan Groen, CEO of MDxHealth. “We are pleased to announce that ConfirmMDx for Prostate Cancer is now available to urologists directly through MDxHealth’s state-of-the-art CLIA laboratory, and via our co-marketing partner PLUS Diagnostics.” Click here For more details on this test.

Tissue biopsies are often not pleasant experiences for anyone having a history of prostate cancer. It is good that the epigenetic tests like the ConfirmMDx(TM) is now on board to help Urologists make informed decision about detecting those with actual prostate cancer. The makers have a track record of manufacturing quality and widely accepted epigenetic diagnostic products. This new product is expected to toe the line of other quality products from the perspective of good effectiveness. So, ConfirmMDx should be applied by Urologists, at least, to test for the claims made by its makers.

Below Are Other Related Articles Among 1,000+Prostate Cancer Articles On This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:(95% of these 1,000+ Prostate Cancer Articles on this website are written by our Expert In -house Writers, after lots of research. The remaining 5% are news articles and videos from relevant sources!)